Guggenheim Upgrades Audentes Therapeutics (BOLD) to Buy
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Price: $2.89 --0%
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
Guggenheim analyst Whitney Ijem upgraded Audentes Therapeutics (NASDAQ: BOLD) from Neutral to Buy with a price target of $35.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $24.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox Advisors Upgrades Dell (DELL) to Overweight
- Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
- William Blair Upgrades GitLab Inc (GTLB) to Market Perform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
